Product Data Sheet

TA-1801

Pathway:

Cat. No.: HY-19030
CAS No.: 88352-44-7

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

Others

BIOLOGICAL ACTIVITY

Description	TA-1801 is a hypolipidemic agent.
In Vitro	TA-1801 inhibits platelet aggregation in vitro $^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TA-1801 reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it is about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Moriya T, et al. Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds. J Med Chem. 1988 Jun;31(6):1197-204.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA